Sunday, May 17, 2026 10:01:12 AM
The 15-business-day window is a strict, high-stakes deadline set by the FDA for companies to respond to a Form 483 before the agency takes harsher legal or regulatory actions.Here is a breakdown of how it works and why it matters:
1. The Clock Starts ImmediatelyThe 15-business-day countdown begins the very next day after the FDA investigators hand the Form 483 to the company's management at the end of an inspection. Weekends and federal holidays do not count toward this total.
2. The Finality of the ResponseThe FDA expects a single, comprehensive response. Companies cannot send piecemeal updates or partial answers. The submission must include:A detailed explanation addressing every single observation listed.A clear Corrective and Preventive Action (CAPA) plan.Hard evidence (e.g., revised standard operating procedures, training logs, or photographs of repairs) proving that fixes are already underway.
3. The Consequences of Missing the WindowIf a company responds on day 16 or later, the FDA is legally permitted to ignore the response during its immediate next steps. The agency will move forward with enforcement actions—such as issuing a formal Warning Letter or withholding drug approvals—based solely on what the investigators saw during the audit, without considering the company's defense or corrections.
The FDA language last time " will prohibit labelling discussions " tanked the stock.
So to honor the 15 business day rule ....FDA must issue a Form 483 ..if its going to by ...rough guess June 10th
Kiwi
Recent UNCY News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2026 08:30:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2026 08:30:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2026 08:30:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/12/2026 11:51:50 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/12/2026 10:30:46 AM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/30/2026 11:04:02 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/30/2026 11:02:10 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/30/2026 11:00:08 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/06/2026 01:11:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/30/2026 11:29:20 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/30/2026 10:32:02 AM
- Unicycive shares gain as FDA accepts resubmitted OLC NDA • IH Market News • 01/29/2026 03:01:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:14 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/14/2025 10:09:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 02:12:01 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2025 11:39:29 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/28/2025 11:30:13 AM
- UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit • PR Newswire (US) • 10/14/2025 06:55:00 AM
